Literature DB >> 21618246

Identification and validation of Kallikrein-ralated peptidase 11 as a novel prognostic marker of gastric cancer based on immunohistochemistry.

Yu-Gang Wen1, Quan Wang, Chong-Zhi Zhou, Dong-Wang Yan, Guo-Qiang Qiu, Chun Yang, Hua-Mei Tang, Zhi-Hai Peng.   

Abstract

BACKGROUND AND OBJECTIVES: It is important to identify and validate the differentially expressed genes in gastric cancer to screen diagnostic and/or prognostic tumor markers.
METHODS: cDNA expression microarray, gene set enrichment analysis, and bioinformatics approaches were used to screen the differentially expressed genes between gastric cancer tissues and adjacent non-cancerous mucosa. A novel candidate prognostic marker, Kallikrein-related peptidase 11 (KLK11), was validated in 400 Chinese gastric cancer patients. KLK11 expression in gastric cancer tissues was detected using real-time PCR and Western blot. KLK11 protein expression was further analyzed by immunostaining on tissue microarray, followed with clinicopathological significance and survival analysis.
RESULTS: KLK11 expression was significantly decreased in gastric cancer compared with that in normal gastric mucosa (P<0.001). Furthermore, KLK11 expression was much lower in poorly differentiated cancer samples than that in well-differentiated group (P<0.01). Survival analysis showed that negative KLK11 expression was associated with nearly fivefold increased risk of distant metastasis after curative gastrectomy (HR 4.65, P<0.01). Multivariate Cox regression analysis showed that KLK11 expression emerged as a significant independent prognostic factor for disease-free survival and overall survival (P<0.05).
CONCLUSIONS: The results indicated that KLK11 expression was decreased in gastric cancer and might serve as a novel independent prognostic marker.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21618246     DOI: 10.1002/jso.21981

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

1.  Clinical significance of human kallikrein 12 gene expression in gastric cancer.

Authors:  En-Hao Zhao; Zhi-Yong Shen; Hua Liu; Xin Jin; Hui Cao
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

2.  SILAC-based quantitative proteomic analysis of gastric cancer secretome.

Authors:  Arivusudar Marimuthu; Yashwanth Subbannayya; Nandini A Sahasrabuddhe; Lavanya Balakrishnan; Nazia Syed; Nirujogi Raja Sekhar; Teesta V Katte; Sneha M Pinto; Srinivas M Srikanth; Praveen Kumar; Harsh Pawar; Manoj K Kashyap; Jagadeesha Maharudraiah; Hassan Ashktorab; Duane T Smoot; Girija Ramaswamy; Rekha V Kumar; Yulan Cheng; Stephen J Meltzer; Juan Carlos Roa; Raghothama Chaerkady; T S Keshava Prasad; H C Harsha; Aditi Chatterjee; Akhilesh Pandey
Journal:  Proteomics Clin Appl       Date:  2013-05-21       Impact factor: 3.494

3.  Identification and validation that up-expression of HOXA13 is a novel independent prognostic marker of a worse outcome in gastric cancer based on immunohistochemistry.

Authors:  Yang Han; Wei-Wei Tu; Yu-Gang Wen; Da-Peng Li; Guo-Qiang Qiu; Hua-Mei Tang; Zhi-Hai Peng; Chong-Zhi Zhou
Journal:  Med Oncol       Date:  2013-04-17       Impact factor: 3.064

4.  Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer.

Authors:  David L Kolin; Keiyan Sy; Fabio Rotondo; Mena N Bassily; Kalman Kovacs; Christine Brezden-Masley; Catherine J Streutker; George M Yousef
Journal:  Tumour Biol       Date:  2015-07-30

5.  The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents.

Authors:  Dimitra Florou; Konstantinos Mavridis; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-09-05

Review 6.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

7.  Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer.

Authors:  Zongbin Xu; Pan Chi; Jie Pan; Songfei Shen; Yanwu Sun; Xiaojie Wang; Xingrong Lu
Journal:  Exp Ther Med       Date:  2016-09-20       Impact factor: 2.447

8.  Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Authors:  Xiaocong Geng; Yueyang Liu; Sandra Diersch; Matthias Kotzsch; Sabine Grill; Wilko Weichert; Marion Kiechle; Viktor Magdolen; Julia Dorn
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

9.  Elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis.

Authors:  Da-Nian Dai; Yan Li; Bo Chen; Yong Du; Shi-Bing Li; Shi-Xun Lu; Zhi-Ping Zhao; Ai-Jun Zhou; Ning Xue; Tian-Liang Xia; Mu-Sheng Zeng; Qian Zhong; Wei-Dong Wei
Journal:  J Mol Med (Berl)       Date:  2017-05-18       Impact factor: 4.599

10.  Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell.

Authors:  Yiyi Zhang; Zongbin Xu; Yanwu Sun; Pan Chi; Xingrong Lu
Journal:  Onco Targets Ther       Date:  2018-02-16       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.